Basilea Pharmaceutica (SIX: BSLN)

Last close As at 20/04/2024


0.25 (0.60%)

Market capitalisation


Basilea Pharmaceutica is focused on treating infectious diseases; marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA broad-spectrum antibiotic). In late 2023, it expanded its pipeline to include BAL2062 (antifungal), tonabacase (antibiotic) and Phase III-ready fosmanogepix (antifungal).

There is an ever-increasing need for therapeutic agents that are efficacious against drug-resistant strains of bacteria (eg MRSA) or fungi. Hence the opportunities for Zevtera and Cresemba could be significant.

Latest Insights

View More



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh


Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Adesh Kaul


  • David Veitch


  • Dung Tran

    Investor relations coordinator

Balance Sheet

Forecast net debt (CHFm)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 19.9 26.7 (4.7)
Relative 24.1 26.2 (3.6)
52 week high/low CHF48.6/CHF32.2


In the lead up to its capital markets day, Basilea Pharmaceutica announced it has received initial funding of up to US$0.9m through a grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership backed by governments and foundations, for its preclinical antibiotics program. CARB-X is focused on supporting early-stage antibacterial research and development, and this grant is expected to support development work up until clinical candidate nomination in H224, with potential additional funding subject to achieving certain milestones. 2024 is shaping up to be an active year for Basilea, following the recent FDA approval and anticipated subsequent commercial launch of Zevtera in the US, as well as the initiation of Phase III studies for newly acquired antifungal asset Fosmanogepix (mid-2024).

Y/E Dec Revenue (CHFm) EBITDA (CHFm) PBT (CHFm) EPS (CHFc) P/E (x) P/CF (x)
2022A 147.8 19.6 12.3 104.10 40.3 N/A
2023A 157.6 20.8 10.8 89.66 46.8 N/A
2024E 187.2 34.0 28.0 233.65 18.0 N/A
2025E 209.1 37.9 32.3 269.24 15.6 N/A

Further insights



Antibiotic resistance




Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest


Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free